Home › Funds › Opaleye Management Inc. › PTGX

Opaleye Management Inc. position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

Opaleye Management Inc. reported holding 100,000 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$12.3M, representing 1.11% of its reported portfolio and ranking #25 among its reported holdings. Opaleye Management Inc. has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)100.00K sh
Reported value held$12.26M
Portfolio Weight1.11%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Opaleye Management Inc.'s PTGX position evolved

Opaleye Management Inc. first disclosed a stake in PTGX in Q4 2023 at 112,700 shares (US$2.6M). The position peaked in Q2 2026 at 100,000 shares, worth US$12.3M. Across 11 filings, Opaleye Management Inc. increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 100,000 shares valued at US$12.3M.

Quarter by quarter

QuarterSharesValueChange
Q4 2023 112.70K $2.58M New
Q1 2024 112.70K $3.26M Hold
Q2 2024 105.00K $3.64M Reduce
Q3 2024 105.00K $4.72M Hold
Q4 2024 105.00K $4.05M Hold
Q1 2025 105.00K $5.08M Hold
Q2 2025 105.00K $5.80M Hold
Q3 2025 105.00K $6.98M Hold
Q4 2025 105.00K $9.17M Hold
Q1 2026 100.00K $10.54M Reduce
Q2 2026 100.00K $12.26M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has Opaleye Management Inc. held PTGX?

Opaleye Management Inc. has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Opaleye Management Inc.'s current position in PTGX?

As of Q2 2026, Opaleye Management Inc. holds 100.00K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $12.26M, representing 1.11% of its reported portfolio and ranking #25.

Has Opaleye Management Inc. been buying or selling PTGX?

In the latest 13F filing (Q2 2026), Opaleye Management Inc. held unchanged its position in PTGX. The position peaked in Q2 2026 at 100.00K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.